Nuvalent (NUVL) Competitors

Nuvalent has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Nuvalent currently has a consensus target price of $127.73, indicating a potential upside of 3.41%. Revolution Medicines has a consensus target price of $123.72, indicating a potential downside of 32.05%. Given Nuvalent's higher probable upside, analysts plainly believe Nuvalent is more favorable than Revolution Medicines.

In the previous week, Revolution Medicines had 7 more articles in the media than Nuvalent. MarketBeat recorded 11 mentions for Revolution Medicines and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.80 beat Revolution Medicines' score of 0.42 indicating that Nuvalent is being referred to more favorably in the media.

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nuvalent's return on equity of -40.11% beat Revolution Medicines' return on equity.

BeOne Medicines has a net margin of 8.94% compared to Nuvalent's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Nuvalent's return on equity.

BeOne Medicines has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Nuvalent has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Nuvalent presently has a consensus price target of $127.73, indicating a potential upside of 3.41%. BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 39.34%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Nuvalent.

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BeOne Medicines had 11 more articles in the media than Nuvalent. MarketBeat recorded 15 mentions for BeOne Medicines and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.80 beat BeOne Medicines' score of 0.13 indicating that Nuvalent is being referred to more favorably in the media.

Nuvalent has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Nuvalent's return on equity.

Nuvalent currently has a consensus target price of $127.73, suggesting a potential upside of 3.41%. Moderna has a consensus target price of $37.13, suggesting a potential downside of 44.80%. Given Nuvalent's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuvalent is more favorable than Moderna.

Nuvalent has higher earnings, but lower revenue than Moderna. Nuvalent is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

In the previous week, Moderna had 18 more articles in the media than Nuvalent. MarketBeat recorded 22 mentions for Moderna and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.80 beat Moderna's score of 0.50 indicating that Nuvalent is being referred to more favorably in the media.

Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioNTech currently has a consensus price target of $129.56, indicating a potential upside of 42.03%. Nuvalent has a consensus price target of $127.73, indicating a potential upside of 3.41%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Nuvalent.

BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Nuvalent has lower revenue, but higher earnings than BioNTech. Nuvalent is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Nuvalent has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Nuvalent's return on equity.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Nuvalent had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Nuvalent and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Nuvalent's score of 0.80 indicating that BioNTech is being referred to more favorably in the media.